Home・Aandelen Lijst・Codexis Inc

Codexis Inc

Gesloten

SectorGezondheidszorg

1.47 -25.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.46

Max

1.55

Belangrijke statistieken
By Trading Economics
Inkomsten	-18M -8.7M
Verkoop	-24M 15M
EPS	-0.1
Winstmarge	-57.083
Werknemers	146
EBITDA	-23M -6.4M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+395.27% upside

Dividenden
By Acuity
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-27M 201M
Vorige openingsprijs	26.85
Vorige sluitingsprijs	1.47

Nieuwssentiment

By Acuity

30%

70%

76 / 340 Rangschikking in Healthcare

Codexis Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 19:01 UTC

News

Codexis Inc shares are lower following a public offering of 16.67 million shares at $1.50 each, below Thursday's close of $1.99.

23 jul 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

22 jul 2026, 20:01 UTC

Codexis Inc shares are lower during Wednesday's session, continuing a trend of declines since Tuesday's close. The stock remains below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Codexis Inc Prognose

Koersdoel

By TipRanks

395.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.33 USD 395.27%

Hoogste 11 USD

Laagste 2 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Codexis Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Codexis Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

76 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.